Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astronics (ATRO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Astronics (ATRO) over the last 16 years, with Q3 2025 value amounting to $13.5 million.

  • Astronics' Cash & Equivalents rose 16036.31% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year increase of 16036.31%. This contributed to the annual value of $9.3 million for FY2024, which is 9522.71% up from last year.
  • Per Astronics' latest filing, its Cash & Equivalents stood at $13.5 million for Q3 2025, which was up 16036.31% from $13.5 million recorded in Q2 2025.
  • Astronics' Cash & Equivalents' 5-year high stood at $33.6 million during Q3 2021, with a 5-year trough of $2.6 million in Q4 2022.
  • In the last 5 years, Astronics' Cash & Equivalents had a median value of $10.7 million in 2022 and averaged $13.9 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 9117.25% in 2022, then skyrocketed by 37112.36% in 2025.
  • Astronics' Cash & Equivalents (Quarter) stood at $29.8 million in 2021, then plummeted by 53.7% to $13.8 million in 2022, then tumbled by 65.48% to $4.8 million in 2023, then surged by 95.23% to $9.3 million in 2024, then surged by 45.17% to $13.5 million in 2025.
  • Its Cash & Equivalents stands at $13.5 million for Q3 2025, versus $13.5 million for Q2 2025 and $24.8 million for Q1 2025.